Rituximab and Hyaluronidase Human Clinical Trials (4 Recruiting)

Recruiting

Phase 3

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Classic Follicular LymphomaFollicular Lymphoma With Unusual Cytological Features

National Cancer Institute (NCI)600 enrolled261 locationsNCT06337318

Recruiting

Phase 2

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

Nodular Lymphocyte Predominant B-Cell LymphomaRecurrent Nodular Lymphocyte Predominant B-Cell LymphomaRefractory Nodular Lymphocyte Predominant B-Cell Lymphoma

National Cancer Institute (NCI)70 enrolled35 locationsNCT05886036

Recruiting

Phase 1Phase 2

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

University of Washington35 enrolled1 locationNCT05455697

Recruiting

Phase 2

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma

Academic and Community Cancer Research United45 enrolled7 locationsNCT04626791